Vectura Group plc Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Vectura Group plcHeadquarters: Chippenham, 
                        United Kingdom
                    
Founded: 1997
Employees: 450

                                show_chart
                                
                                    LSE: VEC
                                
                                            +0.12%
                                            
Market Cap£1.00 Billion

                        GBP as of Oct. 1, 2021
                    
                            US$1.36 Billion
                        
                            history
                            Market Cap History

Vectura Group plc Categories

United Kingdom Healthcare Drug Manufacturers—General

United Kingdom Healthcare

United Kingdom Drug Manufacturers—General

Vectura Group plc market capitalization over time

Evolution of Vectura Group plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Vectura Group plc

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—General

Company	Market Cap (USD)
Johnson & Johnson	$461.85 B
Lilly	$347.61 B
Pfizer	$287.63 B
AbbVie	$285.80 B
Merck	$281.30 B

Sector: Healthcare

Company	Market Cap (USD)
UnitedHealth Group	$495.37 B
Johnson & Johnson	$461.85 B
Lilly	$347.61 B
Novo Nordisk	$304.61 B
Pfizer	$287.63 B

Detailed Description

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.